The Technical Analyst
Alpine Immune Sciences [ALPN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alpine Immune Sciences Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.19% $64.55
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 231.00 mill |
| EPS: | -0.640 |
| P/E: | -100.86 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 65.55 mill |
| Avg Daily Volume: | 2.20 mill |
| RATING 2024-04-19 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -100.86 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -17.16x |
| Company: PE -100.86 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 62.22 - 66.89 ( +/- 3.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Fuhs Ulrich Martin | Sell | 0 | Common Stock |
| 2024-04-03 | Fuhs Ulrich Martin | Sell | 75 000 | Stock Option (Right to buy) |
| 2024-04-03 | Fuhs Ulrich Martin | Sell | 28 700 | Stock Option (Right to buy) |
| 2024-04-03 | Fuhs Ulrich Martin | Sell | 14 600 | Stock Option (Right to buy) |
| 2024-01-25 | Rickey James Paul | Sell | 236 | Stock Option (Right to buy) |
| INSIDER POWER |
|---|
| -21.38 |
| Last 100 transactions |
| Buy: 4 566 792 | Sell: 7 050 513 |
Forecast:
16:00 - $64.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $64.48
Forecast 2: 16:00 - $64.48
Forecast 3: 16:00 - $64.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $64.55 (0.19% ) |
| Volume | 3.98 mill |
| Avg. Vol. | 2.20 mill |
| % of Avg. Vol | 181.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALPN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $28.50 | N/A | Active |
|---|
ALPN
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Latest Press Releases
2024-04-17 19:50:00 - Press Release
Investigation: The M&a Class Action Firm Announces An Investigation Of Alpine Immune Sciences, Inc. - Alpn
New york , april 17, 2024 /prnewswire/ -- monteverde & associates pc (the "m&a class action firm"), has recovered money for shareholders and is recognized as a top 50 firm in the 2018-2022 iss securities class action services report. we are headquartered at the empire state building in new york city and is investigating alpine immune sciences, inc. (nasdaq: alpn), relating to its proposed sale to vertex pharmaceuticals inc..
2024-04-12 17:17:00 - Press Release
Alpine Immune Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Alpine Immune Sciences, Inc. - Alpn
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of alpine immune sciences, inc. (nasdaqgm: alpn) to vertex pharmaceuticals incorporated (nasdaqgs: vrtx). under the terms of the proposed transaction, shareholders of alpine will receive $65.00 in cash for each share of alpine that they own. ksf is seeking to determine whether this consideration and the process t.
2024-04-10 21:50:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Alpine Immune Sciences, Inc. Has Obtained A Fair Price In Its Transaction With Vertex
Milwaukee , april 10, 2024 /prnewswire/ -- ademi llp is investigating alpine (nasdaq: alpn) for possible breaches of fiduciary duty and other violations of law in its transaction with vertex. click here to learn how to join the https://www.ademilaw.com/case/alpine-immune-sciences-inc or call guri ademi toll-free at 866-264-3995.
2024-04-10 20:08:00 - Press Release
Alpn Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Alpine Immune Sciences, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of alpine immune sciences, inc. (nasdaq: alpn) to vertex pharmaceuticals incorporated for $65.00 per share is fair to alpine shareholders. halper sadeh encourages alpine shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whe.
2024-04-10 16:15:00 - Press Release
Alpine Immune Sciences Shares Updated Clinical Data From Povetacicept In Iga Nephropathy
Seattle--(business wire)--alpine immune sciences, inc. (nasdaq: alpn), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in iga nephropathy (igan) which will be presented as a late breaking poster at the world congress of nephrology (wcn) april 13-16, 2024 in buenos aires, argentina. povetacicept is a potent dual antagonist of the baff (b cell activating factor).
Latest News
2024-04-15 15:43:32 - InvestorPlace
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
2024-04-13 05:29:00 - The Motley Fool
Could This Stock Be the Next Biotech Buyout?
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors as Vera Therapeutics' candidate.
2024-04-12 13:41:08 - Zacks Investment Research
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
2024-04-11 13:41:46 - Schaeffers Research
2 Biotech Stocks Driving the Nasdaq Today
The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.
2024-04-11 09:47:56 - InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Drug maker Alpine Immune Sciences (NASDAQ: ALPN ) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ: VRTX ) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial.
2024-04-11 09:23:46 - Invezz
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?
2024-04-11 08:06:00 - Market Watch
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
2024-04-11 07:16:12 - Proactive Investors
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.
2024-04-10 22:45:40 - Investopedia
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
2024-04-10 20:16:19 - GeekWire
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.